Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5097
Title: Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
Authors: van der Westhuizen, Andre 
Lyle, Megan 
Graves, Moira C. 
Zhu, Xiaoqiang 
Wong. Jason W. H. 
Cornall, Kerrie 
Ren, Shu 
Pugliese, Leanna 
Levy, Richard 
Majid, Adeeb 
Vilain, Ricardo E. 
Bowden, Nikola A. 
Issue Date: 2022
Publisher: American Association for Cancer Research
Source: Andre van der Westhuizen, Megan Lyle, Moira C. Graves, Xiaoqiang Zhu, Jason W. H. Wong, Kerrie Cornall, Shu Ren, Leanna Pugliese, Richard Levy, Adeeb Majid, Ricardo E. Vilain, Nikola A. Bowden; Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge. Cancer Research Communications 2 August 2022; 2 (8): 814–826. https://doi.org/10.1158/2767-9764.CRC-22-0128
Journal: Cancer Research Communications
Abstract: Purpose: Drug repurposing offers the opportunity for chemotherapy to be used to reestablish sensitivity to immune checkpoint blockade (ICB) therapy. Here we investigated the clinical and translational aspects of an early phase II study of azacitidine and carboplatin priming for anti-PDL1 immunotherapy (avelumab) in patients with advanced ICB-resistant melanoma. Experimental Design: A total of 20 participants with ICB-resistant metastatic melanoma received 2 × 4-week cycles of azacitidine and carboplatin followed by ICB rechallenge with anti-PD-L1 avelumab. The primary objective was overall response rate after priming and ICB rechallenge. Secondary objectives were clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS). Translational correlation analysis of HLA-A and PD-L1 expression, RNA sequencing, and reduced representation bisulfite sequencing of biopsies at baseline, after priming and after six cycles of avelmuab was performed. Results: The overall response rate (ORR) determined after azacitidine and carboplatin priming was 10% (2/20) with two partial responses (PR). The ORR determined after priming followed by six cycles of avelumab (week 22) was 10%, with 2 of 20 participants achieving immune partial response (iPR). The CBR for azacitidine and carboplatin priming was 65% (13/20) and after priming followed by six cycles of avelumab CBR was 35% (n = 7/20). The median PFS was 18.0 weeks [95% confidence interval (CI): 14.87–21.13 weeks] and the median OS was 47.86 weeks (95% CI: 9.67–86.06 weeks). Translational correlation analysis confirmed HLA-A generally increased after priming with azacitidine and carboplatin, particularly if it was absent at the start of treatment. Average methylation of CpGs across the HLA-A locus was decreased after priming and T cells, in particular CD8+, showed the greatest increase in infiltration. Conclusions: Priming with azacitidine and carboplatin can induce disease stabilization and resensitization to ICB for metastatic melanoma. Significance: There are limited treatments for melanoma once resistance to ICB occurs. Chemotherapy induces immune-related responses and may be repurposed to reinstate the response to ICB. This study provides the first evidence that chemotherapy can provide clinical benefit and increase OS for ICB-resistant melanoma.
Description: Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Megan Lyle
DOI: 10.1158/2767-9764.CRC-22-0128
Type: Article
Appears in Sites:Cairns & Hinterland HHS Publications

Show full item record

Page view(s)

30
checked on Jan 28, 2023

Download(s)

2
checked on Jan 28, 2023

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.